An observational study in Obesity and Overweight, sponsored by Novo Nordisk A/S. Completed at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2022-11-25.
Sponsored by Novo Nordisk A/S · Observational
This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)
-New initiators of liraglutide (unbranded, or branded prescription, i.e. Saxenda® or Victoza®), who have no liraglutide prescriptions in the twelve months prior to index date (time of first prescription). Patients must be research standard (registered as "acceptable" in the database) with at least one year of up-to-standard registration prior to their index date
Exclusion Criteria:
-Not applicable
Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)
Drug: Liraglutide
No treatment given
Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only)
Number
Time frame: Less than 6 months before the date of the first prescription
Number of patients with a BMI above or equal to 27 kg/m^2 and below 30 kg/m^2 and 1 or more comorbidities (Saxenda® only)
With at least 1 relevant comorbidity: (Dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea and/or other weight related comorbidities)
Time frame: Less than 6 months before the date of the first prescription
Number of patients with a BMI above or equal to 27 kg/m^2 and less than 30 kg/m^2 and no comorbidities (Saxenda® only)
None of the relevant comorbidities: (Dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea and/or other weight related comorbidities)
Time frame: Less than 6 months before the first prescription
Number of patients with BMI below 27 kg/m^2 (Saxenda® only)
Number
Time frame: Less than 6 months before the first prescription
Number of patients with less than 5% weight loss and continuing treatment (Saxenda® only)
Number
Time frame: Week 0 (first prescription) to week 16; week 24
Mean weight loss in patients not treated according to stopping rule (Saxenda® only)
Time frame: Week 0 (first prescription) to week 16; week 24
Number of patients with a BMI not measured (Saxenda® only)
Number
Time frame: Less than 6 months before the first prescription
Number of patients with at least 5% weight loss and continuing treatment (Saxenda® only)
Number
Time frame: Week 16 - week 24
Number of patients fulfilling at least one of the following: 1) a prescription interval corresponding to a daily dose of 3.0 mg, 2) dose information of 3.0 mg per day, or 3) indication of weight management (Victoza® only)
Number of patients with Victoza® prescriptions
Time frame: Within 4-12 weeks from the date of the first prescription
Number of initiators with other GLP-1 receptor agonists prescribed during continued treatment with Saxenda® (Saxenda® only)
Continued treatment is defined as no gaps of more than 30 days between assumed prescription end and the subsequent prescription date
Time frame: From date of first prescription until 24 months
Number of initiators with other products for weight management prescribed during continued treatment with Saxenda® (Saxenda® only)
Continued treatment is defined as no gaps of more than 30 days between assumed prescription end and the subsequent prescription date
Time frame: From date of first prescription until 24 months
Number of patients who have reached 3.0 mg (Saxenda® only)
Number
Time frame: 12 weeks from time of first prescription
Number of patients with a treatment duration of 0-6 months (Saxenda® only)
Number
Time frame: Month 6
Number of patients with a treatment duration of 7-12 months (Saxenda® only)
Number
Time frame: Month 12
Number of patients with a treatment duration of 13-18 months (Saxenda® only)
Number
Time frame: Month 18
Number of patients with a treatment duration of 19-24 months (Saxenda® only)
Number
Time frame: Month 24
Number of patients with a treatment duration of 25-36 months (Saxenda® only)
Number
Time frame: Month 36
Number of patients with a treatment duration of 37-48 months (Saxenda® only)
Number
Time frame: Month 48
Number of patients with a treatment duration of 49-60 months (Saxenda® only)
Number
Time frame: Month 60
Number of patients with ongoing treatment (current users) (Saxenda® only)
Number
Time frame: Month 60
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S